Responsive Image

 

 

Responsive Image

Enfermedades inmunomediadas

Líneas de investigación

  • Búsqueda de marcadores biológicos mediante proteómica y genética, para enfermedades autoinmunes sistémicas, con diferentes tipos de muestras, para diagnóstico y pronóstico. Trabajo realizado con el Cic bioGune y diferentes hospitales españoles.
  • Estudios genéticos y ecográficos de la arteria carótida en pacientes diagnosticados de patología musculo-esquelética reumática, para calcular del riesgo cardiovascular de éstos. Trabajo realizado en colaboración con varios hospitales españoles.
  • Registros epidemiológicos, de acontecimientos adversos, riesgo cardiovascular… en pacientes con enfermedades crónicas autoinmunes sistémicas y musculo-esqueléticas. En colaboración con la Sociedad Española de Reumatología y diferentes hospitales españoles.
  • Estudios epidemiológicos en patología reumática y enfermedad inflamatoria intestinal. En colaboración con el servicio de Aparato Digestivo de la OSI Bilbao-Basurto.
  • Utilización de Inteligencia Artificial para realizar estudios de diagnóstico y riesgo cardiovascular en patología inflamatoria y musculo-esquelética reumática. Trabajo conjunto con el servicio de radiodiagnóstico de la OSI Bilbao-Basurto e Ibermática i3B.
  • Estudios de nuevas estragáis y tecnologías para la implantación de servicios modernos de fácil acceso a los pacientes diagnosticados de enfermedades inflamatorias crónicas. Grupo de trabajo de los servicios de Reumatología de los Hospitales Galdakao y Basurto, informática y Araia SI.
  • Ensayos clínicos en todas las fases (l, II, III y IV) en patología Sistémica Autoinmune como Lupus Eritematoso Sistémico, Sindrome de Sjögren, Vasculitis Sistémicas como arteritis de células gigantes, patología musculo-esquelética como Artritis Reumatoide, Espondiloartropatías, enfermedades óseas como la osteoporosis… entre otros. Estudios impulsados por diferentes farmacéuticas.
Foto grupo

Actividades del grupo

El servicio de Reumatología de la OSI Bilbao-Basurto actualmente tiene tres vertientes fundamentales: asistencial, docente e investigadora. En la rama de la actividad investigadora, desde hace más de 30 años se vienen desarrollando estudios epidemiológicos y ensayos clínicos, creando una sobrecarga para los médicos adjuntos. No fue hasta el año 2007 que se contrató mediante BIOEF, personal para crear una unidad de investigación clínica, estableciéndose en el año 2018 el grupo de enfermedades inmunomediadas del ISS Biocruces, que tiene básicamente dos líneas:

  • Ensayos clínicos en todas las fases (I, II, III, IV), tanto en patología autoinmune sistémica, como en patología musculo-esquelética.
  • Investigación Clínica. Realizamos diferentes estudios en búsqueda de biomarcadores mediante proteomica y genética, para el diagnóstico/pronostico tanto en patología autoinmune sistémica como diferentes vasculitis. Registros epidemiológicos de acontecimientos adversos debido a fármacos biológicos, estudios epidemiológicos en pacientes con Enfermedad Inflamatoria Intestinal, estudios de riesgo cardiovascular mediante ecografía y genética de la arteria carótida en pacientes con patología musculoesquelética y autoinmune sistémica. También se está desarrollando nuevas tecnologías telemáticas para facilitar el seguimiento cercano del personal sanitario a los pacientes crónicos. Por último, se está desarrollando herramientas mediante Inteligencia Artificial (IA) para el diagnóstico de patología inflamatoria reumática y la utilización de IAs para reducción del riesgo cardiovascular en pacientes reumáticos.

Todo este inmenso trabajo se puede realizar gracias a la colaboración y el trabajo en sinergia tanto del personal clínico del servicio como del investigador, para poder llevar a cabo los diferentes proyectos con los diferentes servicios de la OSI Bilbao-Basurto, diferentes farmacéuticas, Universidades, Hospitales y sociedades investigadoras.

Coordinador/a del grupo



Miembros del grupo

  María Carmen Muñoz Villafranca
 
 
  Eduardo Cuende Quintana
 
 
  Elena Cintora León
 
 
  Ignacio Torre Salaberri
 
 
  José Francisco García Llorente
 
 
  Natalia Andrea Rivera García
 
 
  Eva Galíndez Agirregoikoa
 
 
  Fernando Diez Renovales
 
 
  Olaia Begoña Fernández Berrizbeitia
 
 
  Maria Jesús Allande López-linares
 
 
  Clara Eugenia Pérez Velásquez
 
 
  María Esther Ruiz Lucea
 
 
  Silvia Pérez Barrio
 
 
  Juan María Blanco Madrigal
 
 
  Ana Rosa Intxaurbe Pellejero
 
 
  Jaime Cardenal Urdampilleta
 
 
  Clara Morandeira Arrizabalaga
 
 
  Ángel José Calderón García
 
 
  Nuria Vegas Revenga
 
 
  Martín Sáenz Aguirre
 
 
  María Enjuanes Noguero
 
 
  Estíbaliz Onís González
 
 
  Irati Urionagüena Onaindia
 
 
  Paula García Ledesma
 
 
  Inés Alonso Sánchez
 
 

Publicaciones del grupo

Gutierrez A, Zapater P, Ricart E, Gonzalez Vivo M, Gordillo J, Olivares D, et al. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. Front Med. 2022; 9: 823900-823900. DOI:10.3389/fmed.2022.823900.

Herrero Morant A, Martin Varillas JL, Castaneda S, Maiz O, Sanchez J, Ortego N, et al. Biologic therapy in refractory Neurobehcet's disease: a multicenter study of 41 patients and literature review. Rheumatology (UK). 2022. DOI:10.1093/rheumatology/keac097.

Eder L, Tony HP, Odhav S, Agirregoikoa EG, Korkosz M, Schwartzman S, et al. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials. Rheumatol Ther. 2022; 9(3): 919-933. DOI:10.1007/s40744-022-00445-w.

Prieto Pena D, Remuzgo Martinez S, Genre F, Ocejo Vinyals JG, Atienza Mateo B, Munoz Jimenez A, et al. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. Clin Exp Rheumatol. 2022; 40(4). DOI:10.55563/clinexprheumatol/8mku9c.

Pulito Cueto V, Remuzgo Martinez S, Genre F, Calvo Alen J, Aurrecoechea E, Llorente I, et al. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clin Exp Rheumatol. 2022; 40(5). DOI:10.55563/clinexprheumatol/p8nx80.

Queiro R, Seoane Mato D, Laiz A, Agirregoikoa EG, Montilla C, Park HS, et al. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning. Front Med. 2022; 9. DOI:10.3389/fmed.2022.891863.

Rueda Gotor J, Ferraz Amaro I, Genre F, Gonzalez Mazon I, Corrales A, Calvo Rio V, et al. Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Semin Arthritis Rheum. 2022; 55: 152037-152037. DOI:10.1016/j.semarthrit.2022.152037.

Prieto Pena D, Remuzgo Martinez S, Genre F, Ocejo Vinyals JG, Atienza Mateo B, Munoz Jimenez A, et al. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. Clin Exp Rheumatol. 2022; 40(4): 727-733

Queiro R, Seoane Mato D, Laiz A, Galindez Agirregoikoa E, Montilla C, Park HS, et al. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis. Clin Exp Rheumatol. 2022. DOI:10.55563/clinexprheumatol/077ul6.

Salgado E, Romera Baures M, Beltran Catalan E, Naredo E, Carreira PE, Garcia Vivar M, et al. Inmune-mediated inflammatory rheumatic diseases in transgender people: A scoping review. Semin Arthritis Rheum. 2022; 52: 151920-151920. DOI:10.1016/j.semarthrit.2021.10.004.

Queiro R, Seoane Mato D, Laiz A, Galindez Agirregoikoa E, Montilla C, Park H, et al. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. Arthritis Res Ther. 2022; 24(1). DOI:10.1186/s13075-022-02838-2.

Aramendi JI, Hamzeh G, Perez C, Gayoso A, Cubero A, Rodriguez R. Rupture of a sinus of Valsalva aneurysm. Repair in a 3-month-old infant. Case report. CIR CARDIOVASC. 2022; 29(3): 185-188. DOI:10.1016/j.circv.2022.01.006.

Julia A, Gomez A, Lopez Lasanta M, Blanco F, Erra A, Fernandez Nebro A, et al. Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis. Ebiomedicine. 2022; 80. DOI:10.1016/j.ebiom.2022.104053.

Remuzgo Martinez S, Rueda Gotor J, Pulito Cueto V, Lopez Mejias R, Corrales A, Lera Gomez L, et al. Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis. Front Immunol. 2022; 13. DOI:10.3389/fimmu.2022.894171.

Ferraz Amaro I, Corrales A, Atienza Mateo B, Vegas Revenga N, Prieto Pena D, Sanchez Martin J, et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis (vol 11, 2363, 2021). Diagnostics. 2022; 12(2). DOI:10.3390/diagnostics12020521.

Rueda Gotor J, Ferraz Amaro I, Genre F, Gonzalez Mazon I, Corrales A, Portilla V, et al. Cardiovascular and disease-related features associated with extra-articular manifestations in axial spondyloarthritis. A multicenter study of 888 patients. Semin Arthritis Rheum. 2022; 57: 152096-152096. DOI:10.1016/j.semarthrit.2022.152096.

Garcia Vivar ML, Rivera N, Galindez Agirregoikoa E, Cuende E, Intxaurbe Pellejero AR, Blanco Madrigal JM, et al. ASYNCHRONOUS TELECONSULTATION BY WHATSAPP CHATBOT IN CONTROLLED AXIAL SPONDYLOARTHRITIS (SPA) PATIENTS UNDER BIOLOGICAL THERAPY: 10 MONTHS EXPERIENCE AT A SINGLE CENTRE. Ann Rheum Dis. 2022; 81: 1087-1087. DOI:10.1136/annrheumdis-2022-eular.3507.

Galindez Agirregoikoa E, Prieto Pena D, Joven Ibanez B, Romero ER, Rusinovich O, Otano JMB, et al. TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF FIRST PATIENTS OF CLINICAL PRACTICE. Ann Rheum Dis. 2022; 81: 1583-1583. DOI:10.1136/annrheumdis-2022-eular.3263.

Garcia Gomez CL, Vega L, Ibarguengoitia O, Enjuanes M, Calvo I, Montero D, et al. ONE YEAR PROGRESSION OF INTERSTITIAL LUNG DISEASE IN CONNECTIVE TISSUE DISEASES. A DESCRIPTIVE STUDY IN A SINGLE TERTIARY CENTER. Ann Rheum Dis. 2022; 81: 1465-1466. DOI:10.1136/annrheumdis-2022-eular.2435.

Vega L, Ibarguengoitia O, Garcia C, Enjuanes M, Galindez Agirregoikoa E, Calvo I, et al. PREGNANCY PLANNING AND FOLLOW-UP IN MULTIDISCIPLINARY UNITS IMPROVES THE OUTCOMES IN WOMEN WITH INFLAMMATORY ARTHROPATHIES. Ann Rheum Dis. 2022; 81: 1260-1260. DOI:10.1136/annrheumdis-2022-eular.2135.

Calderon Goercke M, Loricera J, Moriano C, Castaneda S, Narvaez J, Aldasoro V, et al. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients. Clin Exp Rheumatol. 2022. DOI:10.55563/clinexprheumatol/oqs8u9.

Batista Liz JC, Genre F, Pulito Cueto V, Remuzgo Martinez S, Prieto Pena D, Marquez A, et al. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms. J Clin Med. 2022; 11(19). DOI:10.3390/jcm11195577.

Alvarez Reguera C, Calderon Goercke M, Loricera J, Moriano C, Castaneda S, Narvaez J, et al. OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS. A MULTICENTER REAL-LIFE STUDY OF 471 PATIENTS. Ann Rheum Dis. 2022; 81: 692-693. DOI:10.1136/annrheumdis-2022-eular.3279.

Prieto Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela Casasempere P, et al. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY. Ann Rheum Dis. 2022; 81: 691-692. DOI:10.1136/annrheumdis-2022-eular.2330.

Prieto Pena D, Martinez SR, Genre F, Pulito Cueto V, Atienza Mateo B, Sevilla B, et al. IGA VASCULITIS AND IGA NEPHROPATHY SHARE A SIMILAR IL33-IL1RL1 ASSOCIATION PATTERN. Ann Rheum Dis. 2022; 81: 1201-1203. DOI:10.1136/annrheumdis-2022-eular.414.

Prieto Pena D, Genre F, Martinez SR, Pulito Cueto V, Atienza Mateo B, Sevilla B, et al. BAFF, APRIL Y BAFFR: DIFFERENTIAL BIOMARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?. Ann Rheum Dis. 2022; 81: 1203-1204. DOI:10.1136/annrheumdis-2022-eular.425.

Sanchez Bilbao L, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, et al. INTRAVENOUS VERSUS SUBCUTANEOUS TOCILIZUMAB IN A SERIES OF 471 PATIENTS WITH GIANT CELL ARTERITIS. Ann Rheum Dis. 2022; 81: 379-380. DOI:10.1136/annrheumdis-2022-eular.3260.

Sanchez Bilbao L, Loricera J, Moriano C, Castaneda S, Ferraz Amaro I, Narvaez J, et al. VISUAL INVOLVEMENT AND PERMANENT VISUAL LOSS IN GIANT CELL ARTERITIS: PREDICTIVE FACTORS. Ann Rheum Dis. 2022; 81: 688-689. DOI:10.1136/annrheumdis-2022-eular.2127.

Sanchez Bilbao L, Loricera J, Melero R, Castaneda S, Moriano C, Ferraz Amaro I, et al. INVOLVEMENT OF THE AORTA AND/OR ITS MAIN BRANCHES IN GIANT CELL ARTERITIS. TREATMENT WITH TOCILIZUMAB. Ann Rheum Dis. 2022; 81: 689-690. DOI:10.1136/annrheumdis-2022-eular.2157.

Sanchez Costa JT, Hernandez I, Fernandez E, Silva MT, Jaimes JV, Fernandez IG, et al. TREATMENT, ADVERSE EVENTS AND FOLLOW UP IN PATIENTS WITH GIANT CELL ARTERITIS IN THE ARTESER MULTICENTER STUDY. Ann Rheum Dis. 2022; 81: 686-686. DOI:10.1136/annrheumdis-2022-eular.1314.

Silva RQ, Seoane Mato D, Laiz A, Galindez Agirregoikoa E, Canete JDD, Gratacos Masmitja J, et al. FLARES IN PATIENTS WITH RECENT-ONSET PSORIATIC ARTHRITIS. PREDICTIVE MODEL BASED ON MACHINE LEARNING. Ann Rheum Dis. 2022; 81: 405-406. DOI:10.1136/annrheumdis-2022-eular.1778.

Sanchez Martin J, Loricera J, Moriano C, Castaneda S, Narvaez J, Aldasoro V, et al. TOCILIZUMAB IN NEWLY DIAGNOSED GIANT CELL ARTERITIS VERSUS REFRACTORY/RECURRENT GIANT CELL ARTERITIS; MULTICENTER STUDY OF 471 PATIENTS OF CLINICAL PRACTICE. Ann Rheum Dis. 2022; 81: 698-699. DOI:10.1136/annrheumdis-2022-eular.4027.

Sanchez Martin J, Loricera J, Sanchez Bilbao L, De Miguel E, Melero R, Galindez Agirregoikoa E, et al. ULTRASOUND ASSESSMENT OF THE EFFECTIVENESS OF TOCILIZUMAB IN GIANT CELL ARTERITIS. STUDY OF 26 PATIENTS FROM CLINICAL PRACTICE. Ann Rheum Dis. 2022; 81: 1788-1789. DOI:10.1136/annrheumdis-2022-eular.4098.

Sanchez Martin J, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V, et al. PET ASSESSMENT OF THE EFFECTIVENESS OF TOCILIZUMAB IN GIANT CELL ARTERITIS. STUDY OF 101 PATIENTS FROM CLINICAL PRACTICE. Ann Rheum Dis. 2022; 81: 1789-1790. DOI:10.1136/annrheumdis-2022-eular.4100.

Remuzgo Martinez S, Rueda Gotor J, Pulito Cueto V, Lopez Mejias R, Corrales A, Lera Gomez L, et al. IRISIN: A NEW MARKER OF SUBCLINICAL ATHEROSCLEROSIS, CARDIOVASCULAR RISK AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS?. Ann Rheum Dis. 2022; 81: 414-415. DOI:10.1136/annrheumdis-2022-eular.1058.

Gratacós J, Galíndez E, Otón T. Is Obesity a Predictor for Lack of Response to Treatment in Psoriatic Arthritis? A Systematic Review. Reumatol Clin. 2021; 17(5): 268-278. DOI:10.1016/j.reuma.2019.06.003.

de Toro J, Cea Calvo L, García Vivar ML, Pantoja L, Lerín Lozano C, García Díaz S et al. The Experience With Health Care of Patients With Inflammatory Arthritis: A Cross-sectional Survey Using the Instrument to Evaluate the Experience of Patients With Chronic Diseases. JCR-J Clin Rheumatol. 2021; 27(1): 25-30. DOI:10.1097/RHU.0000000000001155.

Martín Varillas JL, Atienza Mateo B, Calvo Rio V, Beltrán E, Sánchez Bursón J, Adán A et al. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behcet Disease: National Study of 103 White Patients. J Rheumatol. 2021; 48(5): 741-750. DOI:10.3899/jrheum.200300.

Valero Jaimes JA, Lopez Gonzalez R, Martin Martinez MA, Garcia Gomez C, Sanchez Alonso F, Sanchez Costa JT et al. Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. J Clin Med. 2021; 10(3). DOI:10.3390/jcm10030382.

Gonzalez Mazon I, Rueda Gotor J, Ferraz Amaro I, Genre F, Corrales A, Calvo Rio V et al. Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Semin Arthritis Rheum. 2021; 51(2): 395-403. DOI:10.1016/j.semarthrit.2021.02.003.

Prieto Pena D, Remuzgo Martinez S, Ocejo Vinyals JG, Atienza Mateo B, Genre F, Munoz Jimenez A et al. The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clin Exp Rheumatol. 2021; 39 Suppl 129(2): 21-26

Galindez Agirregoikoa E, Prieto Pena D, Martin Varillas JL, Joven B, Rusinovich O, Melero Gonzalez RB et al. Treatment with tofacitinib in refractory psoriatic arthritis. National multicenter study of the first 87 patients of clinical practice. J Rheumatol. 2021; 48(10): 1552-1558. DOI:10.3899/jrheum.201204.

Rueda Gotor J, Lopez Mejias R, Remuzgo Martinez S, Pulito Cueto V, Corrales A, Lera Gomez L et al. Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. Arthritis Res Ther. 2021; 23(1): 111-111. DOI:10.1186/s13075-021-02499-7.

Prieto Pena D, Remuzgo Martinez S, Ocejo Vinyals JG, Atienza Mateo B, Genre F, Jimenez AM et al. The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clin Exp Rheumatol. 2021

Fernandez O, Montalban X, Aladro Y, Alonso A, Arroyo R, Calles C et al. 13th Post-ECTRIMS Meeting: review of the new developments presented at the 2020 ECTRIMS Congress (I). Rev Neurologia. 2021; 72(11): 397-406. DOI:10.33588/rn.7211.2021172.

Prieto Pena D, Remuzgo Martinez S, Ocejo Vinyals JG, Atienza Mateo B, Genre F, Jimenez AM et al. The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clin Exp Rheumatol. 2021; 39(2): 21-26

Prior Espanol A, Sanchez Piedra C, Campos J, Manero FJ, Perez Garcia C, Bohorquez C et al. Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry. Sci Rep. 2021; 11(1): 11091-11091. DOI:10.1038/s41598-021-90442-w.

Prieto Pena D, Genre F, Remuzgo Martinez S, Pulito Cueto V, Atienza Mateo B, Llorca J et al. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Sci Rep. 2021; 11(1): 11510-11510. DOI:10.1038/s41598-021-91055-z.

Maria Alvaro Gracia J, Francisco Garcia Llorente J, Valderrama M, Gomez S, Montoro M. Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review. Rheumatol Ther. 2021; 8(1): 17-40. DOI:10.1007/s40744-020-00258-9.

Alvaro Gracia JM, Barbazan C, Garcia Llorente JF, Munoz Fernandez S, Gomez Centeno A, Urruticoechea Arana A et al. Local adaptation of recommendation-based materials for shared decision-making and management of comorbidity in rheumatoid arthritis. Clin Exp Rheumatol. 2021

Mayordomo L, Collada JM, Hernandez FMF, Bueno A, Insua Vilarino SA, Jimenez Nunez FG et al. Safety in the use of ultrasound in rheumatology during the COVID-19 Pandemic. Spanish Society of Rheumatology positioning paper. Reumatol Clin (Engl Ed). 2021; 17(5): 284-289. DOI:10.1016/j.reuma.2020.10.010.

Gómez Arango C, Gorostiza I, Úcar E, García Vivar ML, Pérez CE, De Dios JR et al. Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial. Rheumatol Ther. 2021; 8(3): 1323-1339. DOI:10.1007/s40744-021-00345-5.

Jose Calderon A, Irabien M. Endoscopic removal by ERCP of a foreign body (bullet) in the common bile duct. Gastrointest Endosc. 2021; 94(1): 194-195. DOI:10.1016/j.gie.2021.02.002.

Morandeira Arrizabalaga C. Rotations abroad: Professional enrichment guaranteed. Radiologia (Engl Ed). 2021; 63(4): 305-306. DOI:10.1016/j.rxeng.2020.05.005.

Fornell Perez R, Merino Bonilla JA, Morandeira Arrizabalaga C, Marin Diez E, Rovira A, Ros Mendoza LH. A bibliometric study of the journal Radiologia during the period 2010-2019. Radiologia. 2021; 63(3): 209-217. DOI:10.1016/j.rx.2021.02.002.

Pulito Cueto V, Remuzgo Martinez S, Genre F, Calvo Alen J, Aurrecoechea E, Llorente I et al. Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clin Exp Rheumatol. 2021

Julia A, Lopez Lasanta M, Blanco F, Gomez A, Haro I, Mas AJ et al. Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. BMC Musculoskelet Disord. 2021; 22(1). DOI:10.1186/s12891-021-04248-y.

Cobo Ibanez T, Sanchez Piedra C, Nuno L, Castellvi I, Carrion Barbera I, Romero Bueno F et al. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology. Reumatol Clin (Engl Ed). 2021. DOI:10.1016/j.reuma.2021.01.007.

Calvo I, Guerrero E, Ibarguengoitia O, Garcia Vivar ML, Fernandez O, Ruiz E et al. EXPERIENCE TO 6 YEARS IN THE MULTIDISCIPLINARY CONSULTATION OF PSORIASIS ARTHROPATHY IN A REFERENCE HOSPITAL. Clin Exp Rheumatol. 2021; 39(5): 1182-1182

Calvo I, Ibarguengoitia O, Montero D, Vega L, Garcia Vivar ML, Ruiz E et al. FREQUENCY AND CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE IN SPONDYLOARTHRITIS WITH BIOLOGICAL THERAPY. Clin Exp Rheumatol. 2021; 39(5): 1215-1215

Calvo I, Ibarguengoitia O, Montero D, Vega L, Garcia CL, Garcia Vivar ML et al. STUDY OF PATIENTS TREATED WITH SECUKINUMAB IN THE SAME HOSPITAL THE LAST TWO YEARS. Clin Exp Rheumatol. 2021; 39(5): 1217-1217

Prieto Pena D, Genre F, Remuzgo Martinez S, Pulito Cueto V, Atienza Mateo B, Llorca J et al. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (vol 11, 11510, 2021). Sci Rep. 2021; 11(1). DOI:10.1038/s41598-021-96114-z.

Prieto Pena D, Remuzgo Martinez S, Genre F, Pulito Cueto V, Atienza Mateo B, Llorca J et al. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Sci Rep. 2021; 11(1). DOI:10.1038/s41598-021-95762-5.

Rueda Gotor J, Lopez Mejias R, Remuzgo Martinez S, Pulito Cueto V, Lera Gomez L, Ladehesa Pineda L et al. VASPIN IN SUBCLINICAL ATHEROSCLEROSIS AND CARDIOVASCULAR RISK IN AXIAL SPONDYLOARTHRITIS. Clin Exp Rheumatol. 2021; 39(5): 1184-1184

Ferraz Amaro I, Rueda Gotor J, Genre F, Corrales A, Blanco R, Portilla V et al. Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Ther Adv Musculoskelet Dis. 2021; 13. DOI:10.1177/1759720X211033755.

Prieto Pena D, Genre F, Martinez SR, Pulito Cueto V, Atienza Mateo B, Sevilla B et al. Vasculitis - aetiology, pathogenesis and animal models. Ann Rheum Dis. 2021; 80: 1076-1077. DOI:10.1136/annrheumdis-2021-eular.766.

Sanchez Bilbao L, Loricera J, Aldasoro V, Melero R, Castaneda S, Maiz O et al. TOCILIZUMAB IN VISUAL INVOLVEMENT OF GIANT CELL ARTERITIS. MULTICENTER STUDY OF 312 PATIENTS OF CLINICAL PRACTICE. Ann Rheum Dis. 2021; 80: 35-36. DOI:10.1136/annrheumdis-2021-eular.2169.

Sanchez Bilbao L, Loricera J, Aldasoro V, Melero R, Castaneda S, Maiz O et al. TOCILIZUMAB IN CRANIAL AND EXTRACRANIAL REFRACTORY GIANT CELL ARTERITIS: A MULTICENTER STUDY OF 312 CASES. Ann Rheum Dis. 2021; 80: 34-35. DOI:10.1136/annrheumdis-2021-eular.2139.

Trallero Araguas E, Romero F, Castellvi I, Ortiz Santamaria V, Castaneda S, Pernaute OS et al. EPIDEMIOLOGICAL AND CLINICAL DIFFERENCES BETWEEN ANTI-MDA5 PHENOTYPES: DATA FROM A LARGE COHORT (MEDRA5) STUDY. Ann Rheum Dis. 2021; 80: 700-700. DOI:10.1136/annrheumdis-2021-eular.3837.

Prieto Pena D, Martinez SR, Genre F, Pulito Cueto V, Atienza Mateo B, Sevilla B et al. BAFF-APRIL-BAFFR PATHWAY ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS. Ann Rheum Dis. 2021; 80: 267-268. DOI:10.1136/annrheumdis-2021-eular.707.

Gracia J, Sanchez Piedra C, Manero J, Ruiz Lucea ME, Lopez Vives L, Bohorquez C et al. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open. 2021; 7(3). DOI:10.1136/rmdopen-2021-001925.

Casbas AG, Zapater P, Ricart E, Gonzalez Vivo M, Gordillo J, Olivares D et al. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry). J Crohns Colitis. 2021; 15: 567-568

Munoz Villafranca C, Ogueta MA, de la Piscina PR, Alvarez Herrero B, Loizate A, Gomez Zabala JM et al. Rescue treatment with original versus biosimilar infliximab in biologic-naive patients with moderate-severe Ulcerative Colitis and corticosteroid failure. J Crohns Colitis. 2021; 15: 475-475. DOI:10.1093/ecco-jcc/jjab076.612.

Munoz Villafranca C, Irabien M, Hernandez Aretxabaleta N, Arreba P, de Zarate JO, Garcia Gomez C et al. Association between anti-TNF alpha drug levels and drug-induced lupus in patients with Inflammatory Bowel Disease. J Crohns Colitis. 2021; 15: 281-282. DOI:10.1093/ecco-jcc/jjab076.360.

Munoz Villafranca C, Goiriena UA, Ispizua N, Munoz MI, Garcia N, de Zaratel JO et al. Potential biomarkers for diagnosis through proteomics, in patients with Inflammatory Bowel Disease. J Crohns Colitis. 2021; 15: 148-149. DOI:10.1093/ecco-jcc/jjab076.164.

Vegas Revenga N, Martin Varillas JL, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Beltran E et al. RAPID IMPROVEMENT IN CYSTOID MACULAR EDEMA WITH HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES. Ann Rheum Dis. 2021; 80: 1225-1226. DOI:10.1136/annrheumdis-2021-eular.3247.

Vegas Revenga N, Martin Varillas JL, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Beltran E et al. HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT OF VISUAL ACUITY IN NON-INFECTIOUS UVEITIS OF DIFFERENT IMMUNE MEDIATED INFLAMMATORY DISEASES. Ann Rheum Dis. 2021; 80: 1412-1412. DOI:10.1136/annrheumdis-2021-eular.2159.

Vegas Revenga N, Martin Varillas JL, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Catalan EB et al. High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases. Arthritis Rheumatol. 2021; 73: 394-396

Vegas Revenga N, Martin Varillas JL, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Catalan EB et al. Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases. Arthritis Rheumatol. 2021; 73: 396-398

De Miguel E, Sanchez Costa JT, Narvaez J, Gonzalez Gay M, Garrido Punal N, Estrada Alarcon PV et al. Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry. Arthritis Rheumatol. 2021; 73: 328-330

Sanchez Bilbao L, Loricera J, Castaneda S, Moriano C, Narvaez J, Aldasoro V et al. Effectiveness of Tocilizumab in Cranial and Extracranial Phenotypes of Giant Cell Arteritis: Multicenter Study of 471 Cases. Arthritis Rheumatol. 2021; 73: 2940-2942

Sanchez Bilbao L, Loricera J, Acha JPV, Moriano C, Narvaez J, Aldasoro V et al. Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice. Arthritis Rheumatol. 2021; 73: 2956-2958

Sanchez Costa JT, Hernandez Rodriguez I, Fernandez E, Silva Diaz MT, Valero Jaimes JA, Gonzalez Fernandez I et al. Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients. Arthritis Rheumatol. 2021; 73: 2946-2948

Delmas AD, Sanchez Bilbao L, Calvo Rio V, Martinez Lopez D, Herrero Morant A, Galindez Agirregoikoa E et al. Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center. Arthritis Rheumatol. 2021; 73: 2743-2745

Queiro R, Coto P, Joven B, Rivera R, Navío Marco T, de la Cueva P, et al. Current Status of Multidisciplinary Care in Psoriatic Arthritis in Spain: NEXUS 2.0 Project. Reumatol Clin. 2020; 16(1): 24-31. DOI:10.1016/j.reuma.2018.01.010.

Sanz J, Beltrán E, Díaz Miguel Pérez MC, Fernández Carballido C, Galíndez E, García Porrua C, et al. Quality Standard for the Management of Patients with Psoriatic Arthritis: QUANTUM Project. Reumatol Clin. 2020; 16(3): 203-215. DOI:10.1016/j.reuma.2018.06.011.

Hernandez Cruz B, Alonso F, Calvo Alen J, Pego Reigosa JM, Lopez Longo FJ, Galindo Izquierdo M, et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry). Lupus. 2020; 29(1): 27-36. DOI:10.1177/0961203319889667.

Fernandez O, Aladro Y, Arroyo R, Brieva LL, Calles Hernandez MC, Carrascal P, et al. [12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)]. Rev Neurologia. 2020; 70(10): 379-390. DOI:10.33588/rn.7010.2020121.

Lopez Mejias R, Genre F, Remuzgo Martinez S, Pulito Cueto V, Sevilla Perez B, Llorca J, et al. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38 Suppl 124(2)

Genre F, Remuzgo Martinez S, Prieto Pena D, Atienza Mateo B, Pulito Cueto V, Llorca J, et al. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38 Suppl 124(2)

Torrente Segarra V, Salman Monte TC, Rua Figueroa I, Del Campo V, Lopez Longo FJ, Galindo Izquierdo M, et al. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER). Semin Arthritis Rheum. 2020; 50(4): 657-662. DOI:10.1016/j.semarthrit.2020.05.016.

Moriano C, Calvo J, Rua Figueroa I, Alvarez ED, Bermudez C, Lopez Longo FJ, et al. FACTORS AFFECTING MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SPAIN IN THE 21ST CENTURY: DATA FROM THE RELESSER REGISTRY. Ann Rheum Dis. 2020; 79: 1049-1050. DOI:10.1136/annrheumdis-2020-eular.5035.

Narvaez J, Sanchez Piedra C, Fernandez Castro M, Martinez Taboada V, Olive A, Rosas J, et al. RISK FACTORS ASSOCIATED WITH RENAL INVOLVEMENT IN PRIMARY SJOGREN'S SYNDROME: DATA FROM THE SPANISH SJOGRENSER COHORT. Ann Rheum Dis. 2020; 79: 670-671. DOI:10.1136/annrheumdis-2020-eular.5149.

Riancho Zarrabeitia L, Martinez Taboada V, Rua Figueroa I, Alonso F, Galindo Izquierdo M, Ovalles J, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus. 2020; 29(12): 1556-1565. DOI:10.1177/0961203320950477.

Pulito Cueto V, Remuzgo Martinez S, Genre F, Calvo Alen J, Aurrecoechea E, Llorente I, et al. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020

Pulito Cueto V, Remuzgo Martinez S, Genre F, Calvo Alen J, Aurrecoechea E, Llorente I, et al. Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2020

Sanchez Bilbao L, Martinez Lopez D, Atienza Mateo B, Martin Varillas JL, Calvo Rio V, Demetrio Pablo R, et al. TOCILIZUMAB IN GRAVES' ORBITOPATHY. MULTICENTER STUDY OF 48 PATIENTS. Ann Rheum Dis. 2020; 79: 846-847. DOI:10.1136/annrheumdis-2020-eular.3651.

Sanchez Bilbao L, Martinez Lopez D, Revenga M, Lopez Vazquez A, Valls Pascual E, Atienza Mateo B, et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med. 2020; 9(9). DOI:10.3390/jcm9092816.

De Miguel E, Llorente JFG, Urrego Laurin C, Garcia Vivar ML, Fernandez Carballido C, Villegas MDCC, et al. SPINAL RADIOGRAPHIC PROGRESSION IN EARLY SPONDYLOARTHRITIS: SIX-YEAR RESULTS FROM THE ESPERANZA COHORT. Ann Rheum Dis. 2020; 79: 1128-1128. DOI:10.1136/annrheumdis-2020-eular.5501.

Julia A, Lasanta ML, Blanco F, Gomez A, Haro I, Mas AJ, et al. SIMULTANEOUS ANALYSIS OF ANTI-CCP, RHEUMATOID FACTOR, ANTI-PAD4 AND ANTI-CARBAMYLATED PROTEIN ANTIBODIES REVEALS INTERACTION EFFECTS WITH RESPONSE TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS. Ann Rheum Dis. 2020; 79: 929-930. DOI:10.1136/annrheumdis-2020-eular.3801.

Vega L, Calvo I, Ibarguengoitia O, Blanco JM, Montero D, Garcia C, et al. REAL LIFE SEVERE INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TREATMENT WITH BIOLOGICAL THERAPY AND JAKI. Ann Rheum Dis. 2020; 79: 977-977. DOI:10.1136/annrheumdis-2020-eular.3691.

Montero D, Ibarguengoitia O, Vega L, Garcia C, Blanco JM, Ruiz ME, et al. PREVALENCE OF HYPOVITAMINOSIS D IN DIAGNOSTIC PATIENTS OF BREAST NEOPLASIA IS GREATER THAN EXPECTED FOR THE GENERAL POPULATION? SERIES OF 200 DIAGNOSTIC PATIENTS OF BREAST NEOPLASIA IN A TERTIARY HOSPITAL INITIATING TREATMENT WITH AROMATASE INHIBITORS. Ann Rheum Dis. 2020; 79: 1751-1752. DOI:10.1136/annrheumdis-2020-eular.5595.

Ibarguengoitia O, Montero D, Vega L, Garcia C, Calvo I, Fernandez O, et al. PREGNANCY AND INFLAMMATORY ARTHROPATIES: EXPERIENCE IN A MULTIDISCIPLINARY UNIT. Ann Rheum Dis. 2020; 79: 1870-1870. DOI:10.1136/annrheumdis-2020-eular.2579.

Tornero C, Villegas MDCC, Juanola Roura X, Garcia Vivar ML, Fernandez Carballido C, Llorente JFG, et al. NO RADIOGRAPHIC SACROILIITIS PROGRESSION OVER 6 YEARS IN PATIENTS WITH EARLY SPONDYLOARTHRITIS FROM THE ESPERANZA COHORT. Ann Rheum Dis. 2020; 79: 750-750. DOI:10.1136/annrheumdis-2020-eular.5450.

Calderon Goercke M, Castaneda S, Aldasoro V, Villa I, Prieto Pena D, Atienza Mateo B, et al. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clin Exp Rheumatol. 2020; 38 Suppl 124(2)

Prieto Pena D, Remuzgo Martinez S, Ocejo Vinyals JG, Atienza Mateo B, Munoz Jimenez A, Ortiz Sanjuan F, et al. Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. Semin Arthritis Rheum. 2020; 50(5): 897-901. DOI:10.1016/j.semarthrit.2020.07.004.

Lopez Mejias R, Genre F, Remuzgo Martinez S, Pulito Cueto V, Sevilla Perez B, Llorca J, et al. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38 Suppl 124(2): 166-170

Genre F, Remuzgo Martinez S, Prieto Pena D, Atienza Mateo B, Pulito Cueto V, Llorca J, et al. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38 Suppl 124(2): 182-187

Calderon Goercke M, Castaneda S, Aldasoro V, Villa I, Prieto Pena D, Atienza Mateo B, et al. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clin Exp Rheumatol. 2020; 38 Suppl 124(2): 112-119

Genre F, Martinez SR, Pulito Cueto V, Prieto Pena D, Atienza Mateo B, Sevilla B, et al. INFLUENCE OF IL17A GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS. Ann Rheum Dis. 2020; 79: 1305-1305. DOI:10.1136/annrheumdis-2020-eular.641.

Martinez SR, Genre F, Pulito Cueto V, Prieto Pena D, Atienza Mateo B, Sevilla B, et al. ROLE OF IRF5 GENE ON THE PATHOGENESIS OF IMMUNOGLOBULIN-A VASCULITIS. Ann Rheum Dis. 2020; 79: 1305-1306. DOI:10.1136/annrheumdis-2020-eular.1023.

Collia Fernandez A, Garcia Sanchez JM, Rivera Perez de Rada P, Fernandez Avellaneda P, Rodrigo Armenteros P, Torre Salaberri I, et al. Recurrent Vertebrobasilar Strokes Associated With Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE). Neurologist. 2020; 25(5): 131-136. DOI:10.1097/NRL.0000000000000273.

Vela P, Sanchez Piedra C, Perez Garcia C, Castro Villegas MC, Freire M, Mateo L, et al. Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register. Arthritis Res Ther. 2020; 22(1): 143-143. DOI:10.1186/s13075-020-02231-x.

Galindez E, Prieto Pena D, Martin Varillas JL, Joven Ibanez B, Rusinovich O, Almodovar R, et al. TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF 87 PATIENTS IN CLINICAL PRACTICE. Ann Rheum Dis. 2020; 79: 1678-1678. DOI:10.1136/annrheumdis-2020-eular.2903.

Fernandez Carballido C, Tornero C, Castro Villegas MC, Galindez E, Garcia Llorente JF, Garcia Vivar ML, et al. No radiographic sacroiliitis progression was observed in patients with early spondyloarthritis at 6 years: results of the Esperanza multicentric prospective cohort. RMD Open. 2020; 6(2). DOI:10.1136/rmdopen-2020-001345.

Acebes C, Andreu JL, Balsa A, Batlle E, de Toro Santos J, Llorente FG, et al. "There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective. Clin Exp Rheumatol. 2020; 38(1): 82-87

Lopez Mejias R, Genre F, Remuzgo Martinez S, Pulito Cueto V, Sevilla Perez B, Llorca J, et al. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38(2): 166-170

Genre F, Remuzgo Martinez S, Prieto Pena D, Atienza Mateo B, Pulito Cueto V, Llorca J, et al. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clin Exp Rheumatol. 2020; 38(2): 182-187

Yanez L, de Ceniga MV, Blanco J, Gonzalez A, Estallo L. Combined treatment of dysphagia lusoria and concomitant ipsilateral carotid artery stenosis. Angiologia. 2020; 72(5): 269-272. DOI:10.20960/angiologia.00143.

Irabien M, Arreba P, Ortiz de Zarate J, Hernandez Aretxabaleta N, de la Maza Ortiz S, Ispizua Madariaga N, et al. Ustekinumab Treatment for Toxic Megacolon in Severe Colonic Crohn's Disease: First Case Report. Rev Esp Enferm Dig. 2020; 113(3): 189-192. DOI:10.17235/reed.2020.7228/2020.

Montero Seisdedos D, Ibarguengoitia Barrena O, Vega Alvarez L, Garcia Gomez CL, Calvo Zorrilla I, Blanco Madrigal JM, et al. Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy. Arthritis Rheumatol. 2020; 72

Vega Alvarez L, Calvo Zorrilla I, Ibarguengoitia Barrena O, Blanco Madrigal JM, Montero Seisdedos D, Garcia Gomez CL, et al. Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors. Arthritis Rheumatol. 2020; 72

Fernandez Diaz C, Castaneda S, Melero R, Ortiz Sanjuan FM, Juan Mas A, Carrasco Cubero C, et al. Abatacetp in Spanish Patients with Arthritis Rheumatoid and Interstitial Lung Disease. Multicenter Study of 263 Patients. Arthritis Rheumatol. 2020; 72

Luis Martin Varillas J, Atienza Mateo B, Calvo Rio V, Beltran Catalan E, Adan A, Hernandez Garfella M, et al. Infliximab in Refractory Uveitis Due to Behcet's Disease: Long Term Follow-up and Therapy Optimization. Multicenter Study of 103 Caucasian Patients. Arthritis Rheumatol. 2020; 72

Moriano C, Calvo Alen J, Rua Figueroa I, Diez Alvarez E, Bermudez C, Lopez Longo FJ, et al. Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry. Arthritis Rheumatol. 2020; 72

Gonzalez Mazon I, Rueda Gotor J, Ferraz Amaro I, Sanchez Bilbao L, Martinez Lopez D, Genre F, et al. Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients. Arthritis Rheumatol. 2020; 72

Gonzalez Mazon I, Ferraz Amaro I, Rueda Gotor J, Sanchez Bilbao L, Martinez Lopez D, Agudo Bilbao M, et al. Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A mutlicenter study with 806 patients. Arthritis Rheumatol. 2020; 72

Fernandez MG, Fernandez OP, Otano JMB, Escudero PG, Stoye C, De Dios JR, et al. COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies. Arthritis Rheumatol. 2020; 72

Escudero PG, Stoye C, Fernandez OP, Fernandez MG, Otano J, De Dios JR, et al. Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection. Arthritis Rheumatol. 2020; 72

Calderon Goercke M, Castaneda S, Aldasoro V, Villa I, Prieto Pena D, Atienza Mateo B, et al. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clin Exp Rheumatol. 2020; 38(2): 112-119

Roeker LE, Scarfo L, Chatzikonstantinou T, Abrisqueta P, Eyre TA, Cordoba R, et al. Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood. 2020; 136. DOI:10.1182/blood-2020-136408.

Silva Fernández L, Otón T, Askanase A, Carreira P, López Longo FJ, Olivé A, et al. Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. Reumatol Clin. 2019; 15(1): 34-42. DOI:10.1016/j.reuma.2017.04.005.

Martínez P, Galve E, Arrazubi V, Sala MÁ, Fernández S, Pérez CE, et al. Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. Reumatol Clin. 2019; 15(4): 211-217. DOI:10.1016/j.reuma.2017.08.005.

Lopez Mejias R, Carmona FD, Genre F, Remuzgo Martinez S, Gonzalez Juanatey C, Corrales A, et al. Identification of a 3'-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study. Arthritis Rheumatol. 2019; 71(3): 351-360. DOI:10.1002/art.40734.

Queiro R, Laiz A, Seoane Mato D, Galindez Agirregoikoa E, Montilla C, Park HS, et al. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology. Reumatol Clin. 2019; 15(5): 252-257. DOI:10.1016/j.reuma.2018.09.008.

Orozco Beltrán D, de Toro J, Galindo MJ, Marín Jiménez I, Casellas F, Fuster RuizdeApodaca MJ, et al. Healthcare Experience and their Relationship with Demographic, Disease and Healthcare-Related Variables: A Cross-Sectional Survey of Patients with Chronic Diseases Using the IEXPAC Scale. Patient. 2019; 12(3): 307-317. DOI:10.1007/s40271-018-0345-1.

Rosas J, Sanchez Piedra C, Fernandez Castro M, Andreu JL, Martinez Taboada V, Olive A, et al. ESSDAI activity index of the SJoGRENSER cohort: analysis and comparison with other European cohorts. Rheumatol Int. 2019; 39(6): 991-999. DOI:10.1007/s00296-019-04285-w.

de Miguel E, Joven Ibanez B, Galindez E, Urrego Laurin C, Luz Garcia Vivar M, Fernandez Carballido C, et al. THE VALUE OF SACROILIAC JOINT RADIOGRAPHS IN THE EARLY SPONDYLOARTHRITIS ESPERANZA COHORT. Ann Rheum Dis. 2019; 78(2): 472-472. DOI:10.1136/annrheumdis-2019-eular.7696.

Tornero C, Urrego Laurin C, Luz Garcia Vivar M, Fernandez Carballido C, Juanola Roura X, Garcia Llorente JF, et al. RELIABILITY OF SACROILIAC JOINT RADIOGRAPHS IN THE EARLY SPONDYLOARTHRITIS ESPERANZA COHORT. Ann Rheum Dis. 2019; 78(2): 1821-1821. DOI:10.1136/annrheumdis-2019-eular.7768.

Calvo I, Ibarguengoitia O, Montero D, Vega L, Garcia ML, Galindez E, et al. MULTIPLE BONE INFARCTS WITHIN THE PPP SYNDROME CONTEXT: A HARDLY KNOWN BONE AFFECTATION - A CASE REPORT. Osteoporosis Int. 2019; 30(2): 448-448

Ibarguengoitia O, Blanco JM, Calvo I, Montero D, Vega L, Galindez E, et al. BONE INVOLVEMENT IN SYSTEMIC MASTOCYTOSIS: CASE SERIES FROM A SINGLE CENTER. Osteoporosis Int. 2019; 30(2): 415-416

Montero D, Cuende E, Galindez E, Ruiz E, Torre I, Intxaurbe AR, et al. DIAGNOSIS OF MCCUNE ALBRIGHT SYNDROME IN A PATIENT FOLLOWED ON A RHEUMATOLOGY CONSULT OF OSTEOPOROSIS. Osteoporosis Int. 2019; 30(2): 761-762

Vega L, Calvo I, Ibarguengoitia O, Montero D, Garcia Vivar ML, Ruiz E, et al. DIAGNOSIS OF PSEUDOPSEUDOHYPOPARATHYROIDISM IN A PATIENT ON A RHEUMATOLOGY CONSULT. Osteoporosis Int. 2019; 30(2): 633-634

Riancho Zarrabeitia L, Martinez Taboada V, Rua Figueroa I, Sanchez Alonso F, Galindo Izquierdo M, Ovalles J, et al. DO ALL ANTIPHOSPHOLIPID ANTIBODIES CONFER THE SAME RISK FOR MAJOR ORGAN INVOLVEMENT IN SLE PATIENTS?. Ann Rheum Dis. 2019; 78(2): 136-137. DOI:10.1136/annrheumdis-2019-eular.2485.

Cobo Ibanez T, Urruticoechea Arana A, Rua Figueroa I, Auxiliadora Martin Martinez M, Ovalles J, Galindo Izquierdo M, et al. HORMONE DEPENDENCE AND CANCER IN SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis. 2019; 78(2): 404-404. DOI:10.1136/annrheumdis-2019-eular.5975.

Luis Andreu J, Sanchez Piedra C, Fernandez Castro M, Martinez Taboada V, Olive A, Rosas J, et al. NERVOUS SYSTEM INVOLVEMENT IN PRIMARY SJOGREN'S SYNDROME. Ann Rheum Dis. 2019; 78(2): 407-407. DOI:10.1136/annrheumdis-2019-eular.3607.

Garcia Vivar LM, de Toro Santos J, Pantoja L, Lerin Lozano C, Garcia Diaz S, Fernandez S, et al. FACTORS RELATED TO NON-ADHERENCE BEHAVIORS OF PATIENTS WITH RHEUMATIC DISEASES. Ann Rheum Dis. 2019; 78(2): 604-605. DOI:10.1136/annrheumdis-2019-eular.2773.

Ibarguengoitia O, Ruiz ME, Calvo I, Montero D, Vega L, Blanco JM, et al. 15-YEAR EXPERIENCE IN A MULTIDISCIPLINARY UNIT FOR THE FOLLOW-UP OF PREGNANCY IN RHEUMATIC INFLAMATORY AND AUTOIMMUNE DISEASES. Ann Rheum Dis. 2019; 78(2): 800-800. DOI:10.1136/annrheumdis-2019-eular.2278.

Calvo I, Ibarguengoitia O, Montero D, Vega L, Maria L, Ruiz ME, et al. FREQUENCY AND CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE IN SPONDYLOARTHRITIS WITH BIOLOGICAL THERAPY. STUDY OF 270 PATIENTS FROM THE SAME CENTER. Ann Rheum Dis. 2019; 78(2): 1238-1239. DOI:10.1136/annrheumdis-2019-eular.4427.

Tony H, Galindez E, Sprabery AT, Gellett AM, Lin C, Park SY, et al. IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS WITH IXEKIZUMAB COMPARED TO PLACEBO IN PATIENT SUBGROUPS DEFINED BY BASELINE DISEASE CHARACTERISTICS. Ann Rheum Dis. 2019; 78(2): 1285-1285. DOI:10.1136/annrheumdis-2019-eular.1620.

Fernandez Diaz C, Loricera J, Castaneda S, Juan Mas A, Carrasco Cubero C, Casafont Sole I, et al. ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE. A MULTICENTRE STUDY OF 181 PATIENTS. Ann Rheum Dis. 2019; 78(2): 1617-1618. DOI:10.1136/annrheumdis-2019-eular.6091.

Atienza Mateo B, Luis Martin Varillas J, Calvo Rio V, Demetrio Pablo R, Beltran E, Sanchez Burson J, et al. COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHCET'S DISEASE. NATIONAL MULTICENTER STUDY OF 177 CASES. Ann Rheum Dis. 2019; 78(2): 814-815. DOI:10.1136/annrheumdis-2019-eular.1606.

Luis Martin Varillas J, Galindez E, Rubio Romero E, Sellas Fernandez A, Gonzalez Benitez RD, Joven Ibanez B, et al. TREATMENT WITH TOFACITINIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF CLINICAL PRACTICE. Ann Rheum Dis. 2019; 78: 1848-1849. DOI:10.1136/annrheumdis-2019-eular.7803.

Luis Martin Varillas J, Gonzalez Mazon I, Atienza Mateo B, Calderon Goercke M, Prieto Pena D, Sanchez Bilbao L, et al. BIOLOGICAL THERAPYIN NEUROBEHCET. MULTICENTER STUDY OF 29 PATIENTS. Ann Rheum Dis. 2019; 78: 1193-1194. DOI:10.1136/annrheumdis-2019-eular.7591.

Atienza Mateo B, Luis Martin Varillas J, Calvo Rio V, Demetrio Pablo R, Valls Pascual E, Valls Espinosa B, et al. ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES' ORBITOPATHY. MULTICENTER STUDY OF 46 PATIENTS IN CLINICAL PRACTICE. Ann Rheum Dis. 2019; 78: 2003-2003. DOI:10.1136/annrheumdis-2019-eular.1628.

Almodóvar R, Bueno Á, Batlle E, Beltrán Catalán E, Bernabeu D, Castro Copete C, et al. Magnetic resonance imaging assessment in patients with axial spondyloarthritis: development of checklists for use in clinical practice. Rheumatol Int. 2019; 39(12): 2119-2127. DOI:10.1007/s00296-019-04441-2.

Calderón Goercke M, Loricera J, Aldasoro V, Castañeda S, Villa I, Humbría A, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019; 49(1): 126-135. DOI:10.1016/j.semarthrit.2019.01.003.

Perez Velasquez C, Ibarguengoitia Barrena O, Montero Seisdedos D, Vega Alvarez L, Garcia Gomez C, Galindez Agirregoikoa E, et al. Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results. Arthritis Rheumatol. 2019; 71(10)

Calvo Zorrilla I, Luz Garcia Vivar M, Ibarguengoitia Barrena O, Montero Seisdedos D, Vega Alvarez L, Maria Blanco Madrigal J, et al. Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center. Arthritis Rheumatol. 2019; 71(10)

Calvo I, Ibarguengoitia O, Montero D, Vega L, Maria L, Ruiz ME, et al. DIFFERENCES AND CHARACTERISTICS OF PRIMARY LARGE VESSEL VASCULTIS AND LARGE VESSEL VASCULITIS ASSOCIATED WITH GIANT CELL ARTERITIS. STUDY OF 28 CASES FROM THE SAME CENTER. Ann Rheum Dis. 2019; 78: 1750-1751. DOI:10.1136/annrheumdis-2019-eular.4694.

Riancho Zarrabeitia L, Martinez Taboada VM, Figueroa IR, Alonso F, Galindo M, Ovalles Bonilla J, et al. Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients?. Arthritis Rheumatol. 2019; 71(10)

Riancho Zarrabeitia L, Martinez Taboada VM, Rua Figueroa I, Alonso F, Galindo M, Ovalles Bonilla J, et al. Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease. Arthritis Rheumatol. 2019; 71(10)

de Toro Santos J, Garcia Vivar LM, Pantoja L, Lerin Lozano C, Garcia Diaz S, Mestre Y, et al. ASSESSMENT OF RHEUMATIC DISEASES PATIENTS EXPERIENCE WITH THEIR HEALTHCARE USING IEXPAC. FACTORS ASSOCIATED AND AREAS OF IMPROVEMENT. Ann Rheum Dis. 2019; 78(2): 2065-2066. DOI:10.1136/annrheumdis-2019-eular.2759.

Genre F, Rueda Gotor J, Remuzgo Martinez S, Pulito Cueto V, Corrales A, Mijares V, et al. Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients. Arthritis Rheumatol. 2019; 71(10)

Calderon Goercke M, Loricera J, Prieto Pena D, Castaneda S, Caceres VA, Villa I, et al. Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution. Arthritis Rheumatol. 2019; 71

Calderon Goercke M, Loricera J, Prieto Pena D, Castaneda S, Caceres VA, Villa I, et al. Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous. Arthritis Rheumatol. 2019; 71

Calderon Goercke M, Loricera J, Prieto Pena D, Castaneda S, Caceres VA, Villa I, et al. Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone. Arthritis Rheumatol. 2019; 71

Calderon Goercke M, Loricera J, Prieto Pena D, Castaneda S, Caceres VA, Villa I, et al. Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients. Arthritis Rheumatol. 2019; 71

Gonzalez Mazon I, Sanchez Bilbao L, Martin Varillas JL, Atienza Mateo B, Rio VC, Castaneda S, et al. Biological Therapy in Neurobehcet: Multicenter Study of 31 Patients. Arthritis Rheumatol. 2019; 71

Prieto Pena D, Calderon Goercke M, Loricera J, Narvaez J, Aurrecoechea E, Villa I, et al. Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement. Arthritis Rheumatol. 2019; 71

Emperiale V, Sanchez Piedra C, Bohorquez C, Colazo M, Fernandez Lopez C, Busquets N, et al. EFFECTIVENESS OF BIOLOGIC THERAPY ON DISEASE ACTIVITY IN ANKYLOSING SPONDYLITIS: A BIOBADASER III OBSERVATIONAL STUDY. Ann Rheum Dis. 2019; 78: 879-880. DOI:10.1136/annrheumdis-2019-eular.214.

Calderon Goercke M, Loricera J, Prieto Pena D, Caceres VA, Castaneda S, Villa I, et al. Tocilizumab in Aortitis: A Multicenter Study of 79 Patients. Arthritis Rheumatol. 2019; 71

Calderon Goercke M, Loricera J, Prieto Pena D, Castaneda S, Caceres VA, Villa I, et al. Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms. Arthritis Rheumatol. 2019; 71

Fernández Díaz C, Loricera J, Castañeda S, López Mejías R, Ojeda García C, Olivé A, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum. 2018; 48(1): 22-27. DOI:10.1016/j.semarthrit.2017.12.012.

Gratacós J, Luelmo J, Rodríguez J, Notario J, Marco TN, de la Cueva P, et al. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. Rheumatol Int. 2018; 38(6): 1115-1124. DOI:10.1007/s00296-018-3986-4.

Martín Varillas JL, Calvo Río V, Beltrán E, Sánchez Bursón J, Mesquida M, Adán A, et al. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology. 2018; 125(9): 1444-1451. DOI:10.1016/j.ophtha.2018.02.020.

Marzo Ortega H, Meroni P, Galindez Agirregoikoa E, Behrens F, Bradley AJ, Leage SL, et al. EFFICACY AND SAFETY OF IXEKIZUMAB AT WEEK 24 IN BIOLOGIC EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SUMMARY RESULTS. Rheumatology (Oxford). 2018; 57(3)

Flórez MT, Almodóvar R, García Pérez F, Rodríguez Cambrón AB, Carmona L, Pérez Manzanero MÁ, et al. The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. Rheumatol Int. 2018; 38(7): 1277-1284. DOI:10.1007/s00296-018-4049-6.

Montero D, Ruiz E, Fernandez O, Torre I, Intxaurbe AR, Perez C, et al. MONOTHERAPY WITH BIOLOGICS VS COMBINED THERAPY IN PATIENTS WITH PSORIATIC ARTHRITIS (APSOR) PERIPHERAL. Clin Exp Rheumatol. 2018; 36(4): 729-730

Fernandez Berrizbeitia O, Gonzalezdegaraday M, Garcia Vivar ML, Lopez Medina A, Ruiz Lucea E, Torre Salaberri I, et al. USEFULNESS OF VERTEBROPLASTY IN VERTEBRAL FRACTURES WITH PERSISTANT BACK PAIN: A REPORT OF 64 VERTEBRAL AUGMENTATION FROM A UNIVERSITY HOSPITAL. Osteoporosis Int. 2018; 29(1): 233-234

Marzo Ortega H, Meroni P, Galindez Agirregoikoa E, Behrens F, Bradley A, Leage SL, et al. Efficacy and safety of ixekizumab at week 24 in biologic-experienced patients with active psoriatic arthritis: summary results. Scand J Rheumatol. 2018; 47(129): 43-44

Carmona L, Galindez E. OBESITY INTERACTS WITH RESPONSE AND INCREASES THE RISK OF HYPERTRANSAMINEMINA IN PSORIATIC ARTHRITIS. Clin Exp Rheumatol. 2018; 36(1): 70-70

Deza G, Notario J, Ferran M, Beltrán E, Almirall M, Alcalá R, et al. Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain. Rheumatol Int. 2018; 38(11): 2037-2043. DOI:10.1007/s00296-018-4144-8.

Vegas Revenga N, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Beltran E, Follonosa A, et al. HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE INDUCES RAPID IMPROVEMENT IN SEVERE UVEITIS: A MULTICENTER STUDY OF 129 PATIENTS. Ann Rheum Dis. 2018; 77: 1162-1163. DOI:10.1136/annrheumdis-2018-eular.3780.

Fernandez Diaz C, Castaneda S, Garcia Magallon B, Narvaez Garcia J, Retuerto M, Perez Sandoval T, et al. RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE. MULTICENTRIC RETROSPECTIVE STUDY OF 118 PATIENTS TREATED WITH BIOLOGICAL NO ANTI TNF. Ann Rheum Dis. 2018; 77: 312-312. DOI:10.1136/annrheumdis-2018-eular.4986.

Atienza Mateo B, Calvo Rio V, Martin Varillas JL, Demetrio Pablo R, Beltran E, Gandia M, et al. COMPARATIVE STUDY OF INFLIXIMAB VERSUS ADALIMUMAB IN REFRACTORY UVEITIS ASSOCIATED TO CYSTOID MACULAR OEDEMADUE TO BEHCET'S DISEASE. MULCITENTER STUDY OF 40 CASES. Ann Rheum Dis. 2018; 77: 431-432. DOI:10.1136/annrheumdis-2018-eular.3891.

Atienza Mateo B, Calvo Rio V, Martin Varillas JL, Demetrio Pablo R, Valls Pascual E, Valls Espinosa B, et al. ANTI-IL6-RECEPTOR TOCILIZUMAB IN GRAVES' ORBITOPATHY. MULTICENTER STUDY OF 29 PATIENTS. Ann Rheum Dis. 2018; 77: 1153-1154. DOI:10.1136/annrheumdis-2018-eular.4830.

Luis Martin Varillas J, Atienza Mateo B, Calvo Rio V, Calderon Goercke M, Prieto Pena D, Demetrio Pablo R, et al. Treatment of Refractory Cystoid Macular Edema to Conventional Immunosuppressive Therapy: Tocilizumab Vs Anti-TNF-Alpha. Multicenter Study of 59 Patients. Arthritis Rheumatol. 2018; 70

Luis Martin Varillas J, Atienza Mateo B, Calvo Rio V, Pena DP, Calderon Goercke M, Pena Sainz Pardo E, et al. Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behcet's Disease. Arthritis Rheumatol. 2018; 70

Luis Martin Varillas J, Atienza Mateo B, Calvo Rio V, Prieto Pena D, Calderon Goercke M, Demetrio Pablo R, et al. Infliximab Therapy in Refractory Retinal Vasculitis of Behcet's Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients. Arthritis Rheumatol. 2018; 70

Atienza Mateo B, Luis Martin Varillas J, Calvo Rio V, Demetrio Pablo R, Prieto Pena D, Calderon Goercke M, et al. Anti-IL6-Receptor Tocilizumab in Graves' Orbitopathy. Multicenter Study of 46 Patients. Arthritis Rheumatol. 2018; 70

Vegas Revenga N, Calvo Rio V, Gonzalez Mazon I, Sanchez Bilbao L, Beltran E, Fonollosa A, et al. High Dose Intravenous Methylprednisolone Induces Rapid Improvement in Severe Non-Infectious Uveitis. a Multicenter Study of 120 Patients. Arthritis Rheumatol. 2018; 70

Atienza Mateo B, Luis Martin Varillas J, Calvo Rio V, Demetrio Pablo R, Beltran E, Mesquida M, et al. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis Due to Behcet's Disease. National Multicenter Study of 177 Cases. Arthritis Rheumatol. 2018; 70

Perez Velasquez C, Vivar MLG, Barrio SP, Galindez Agirregoikoa E, Lucea ER, Torre Salaberri I, et al. Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit. Arthritis Rheumatol. 2018; 70

Perez Velasauez CE, Garcia Vivar ML, Perez Barrio S, Galindez Agirregoikoa E, Ruiz Lucea E, Torre Salaberri I, et al. CLINICAL RESULTS OF PATIENTS WITH PERIPHERAL PSORIATIC ARTHRITIS NOT RECEIVING BIOLOGICAL THERAPY IN A MULTIDISCIPLINARY UNIT. Ann Rheum Dis. 2018; 77: 366-367. DOI:10.1136/annrheumdis-2018-eular.4880.

Goercke MC, Loricera J, Pena DP, Narvaez FJ, Aurrecoechea E, Villa Blanco I, et al. Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis. Arthritis Rheumatol. 2018; 70

Goercke MC, Loricera J, Pena DP, Aldasoro V, Castaneda S, Villa Blanco I, et al. Tocilizumab in Giant Cell Arteritis. National Multicenter Study of 134 Patients of Clinical Practice. Arthritis Rheumatol. 2018; 70

Pena DP, Loricera J, Goercke MC, Narvaez FJ, Aurrecoechea E, Villa Blanco I, et al. Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT. Arthritis Rheumatol. 2018; 70

Goercke MC, Loricera J, Pena DP, Aldasoro V, Castaneda S, Villa Blanco I, et al. A Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice in Treatment with Tocilizumab Compared with Giacta Trial. Arthritis Rheumatol. 2018; 70

Zorrilla IC, Basterretxea EG, Ibarguengoitia O, Montero D, Vivar MLG, Lucea ER, et al. Frequency and Pattern of the Uveitis in Spondyloarthritis with Biological Therapy. Arthritis Rheumatol. 2018; 70

Zorrilla IC, Basterretxea EG, Ibarguengoitia O, Montero D, Vivar MLG, Lucea ER, et al. Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center. Arthritis Rheumatol. 2018; 70

Martin Varillas JL, Loricera J, Prieto Pena D, Narvaez J, Aurrecoechea E, Villa I, et al. EXTRACRANIAL VASCULAR AFFECTION IN GIANT CELL ARTERITIS. Ann Rheum Dis. 2018; 77: 777-778. DOI:10.1136/annrheumdis-2018-eular.4191.

Rivera N, Ruiz E, Ucar E, Vivar MLG, Elortza F, Azkargorta M, et al. URINARY PROTEIN PROFILE COMPARISON BETWEEN SLE PATIENTS WITH AND WITHOUT RENAL INVOLVEMENT. Ann Rheum Dis. 2018; 77: 1772-1772. DOI:10.1136/annrheumdis-2018-eular.3720.

Ibarguengoitia O, Ruiz E, Garcia ML, Kapetanovic S, Fernandez O, Torre I, et al. DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS DIAGNOSED WITH INFLAMMATORY MYOSITIS IN A TERTIARY HOSPITAL. Ann Rheum Dis. 2018; 77: 1529-1529. DOI:10.1136/annrheumdis-2018-eular.2639.

Jolly M, Devilliers H, Rua Figueroa I, Azizoddin DR, Almagro RM, Longo FJL, et al. Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort. Arthritis Rheumatol. 2018; 70

Jolly M, Azizoddin DR, Rua Figueroa I, Devilliers H, Almagro RM, Javier FJL, et al. Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort. Arthritis Rheumatol. 2018; 70

Pego Reigosa JM, Salman Monte TC, Altabas Gonzalez I, Rua Figueroa I, J, Balboa Barreiro V, et al. Relationship between Damage and Mortality in Juvenile-Onset Systemic Lupus Erythematosus: Cluster Analyses in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry. Arthritis Rheumatol. 2018; 70

Calvo I, Guerrero E, Ibarguengoitia O, Montero D, Garcia ML, Ruiz E, et al. FREQUENCY AND PATTERN OF THE UVEITIS IN SPONDYLOARTHRITIS WITH BIOLOGICAL THERAPY. Ann Rheum Dis. 2018; 77: 348-349. DOI:10.1136/annrheumdis-2018-eular.4103.

Torrente Segarra V, Salman Monte TC, Rúa Figueroa I, De Uña Álvarez J, Balboa Barreiro V, López Longo FJ, et al. Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Semin Arthritis Rheum. 2018; 70(9): 1025-1029. DOI:10.1016/j.semarthrit.2018.09.005.

Narváez J, Borrell H, Sánchez Alonso F, Rúa Figueroa I, López Longo FJ, Galindo Izquierdo M, et al. Primary respiratory disease in patients with systemic lupus erythematosus: Data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Res Ther. 2018; 20(1): 280-280. DOI:10.1186/s13075-018-1776-8.

Goercke MC, Loricera J, Pena DP, Morales CM, Alvarez ED, Narvaez F, et al. Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis. Arthritis Rheumatol. 2018; 70

Martin Varillas JL, Calvo Rio V, Demetrio Pablo R, Atienza Mateo B, Loricera J, Hernandez MV, et al. COMPARATIVE STUDY OF THE TREATMENT OF REFRACTORY CYSTOID MACULAR OEDEMA TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY: TOCILIZUMAB VS ANTI-TNF. MULTICENTER STUDY OF 59 PATIENTS. Ann Rheum Dis. 2018; 77: 776-777. DOI:10.1136/annrheumdis-2018-eular.3999.

Oton T, Loza E, Beltran E, Diaz Miguel C, Fernandez Carballido C, Galindez E, et al. QUALITY STANDARD FOR THE MANAGEMENT OF PATIENTS WITH PSORIATIC ARTHRITIS: QUANTUM PROJECT. Ann Rheum Dis. 2018; 77: 1728-1729. DOI:10.1136/annrheumdis-2018-eular.5455.

Martin Varillas JL, Calvo Rio V, Beltran E, Sanchez J, Mesquida M, Adan A, et al. MAINTENANCE TREATMENT WITH ADALIMUMAB IN REFRACTORY UVEITIS DUE TO BEHCET'S DISEASE: OPTIMISED VS NON-OPTIMISED GROUP. Ann Rheum Dis. 2018; 77: 1478-1479. DOI:10.1136/annrheumdis-2018-eular.3963.

de Toro J, Cea Calvo L, Garcia Vivar ML, Pantoja L, Lerin C, Garcia Diaz S, et al. THE EXPERIENCE OF PATIENTS WITH DIFFERENT CHRONIC DISEASES WITH HEALTH CARE. A SURVEY WITH THE IEXPAC INSTRUMENT. Ann Rheum Dis. 2018; 77: 1804-1805. DOI:10.1136/annrheumdis-2018-eular.1588.

Garcia Vivar ML, Cea Calvo L, de Toro J, Pantoja L, Lerin C, Garcia Diaz S, et al. SELF-ASSESSMENT OF QUALITY OF LIFE OF PATIENTS WITH RHEUMATIC DISEASES AND OTHER CHRONIC DISEASES IN THE IEXPAC PROJECT. Ann Rheum Dis. 2018; 77: 1807-1808. DOI:10.1136/annrheumdis-2018-eular.2675.

© 2022 IIS Biocruces Bizkaia